- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, announced an interview with Dr. Joseph Vallner as the most recent installment of its 2007 Lumera Experts Podcasting Series. Vallner is the President and CEO of Capnia, a private bioscience company, and a member of Lumera's Board of Directors.
Capnia is testing its intranasal therapeutic gas to alleviate migraine and allergic rhinitis through the gas affect on the trigeminal nerve. Inhibition of the release of calcitonin gene related peptide is the hypothesized mechanism.
"My interest in Lumera centers on its bioscience capabilities, specifically the advanced optics surrounding the ProteomicProcessor™ development," said Vallner in his podcast interview. "The ability to understand proteins and antigens are at the core of unleashing the potential of personalized medicine area. The biomarker work that Lumera is doing with accurate predictive diagnosis can be very beneficial to thousands of patients."
"Lumera has been very fortunate in attracting the interest of global experts in fields of bioscience and electro-optics, and their contributions have a significant impact on our choice of direction for commercializing our proprietary technology," commented Lumera Chief Executive Officer Tom Mino. "The company and its shareholders will benefit from this outside expertise, and we value the contributions that Dr. Vallner makes to Lumera as he shares his considerable experience through his board participation."
Earlier this year, Lumera announced the 2007 Lumera Experts Podcast Series, featuring interviews with industry leaders who are familiar with Lumera's technology and are experts in nanotechnology, bio-arrays, drug discovery, electro-optics, and wireless technologies. Podcast interviews by Dr. Niro Ramachandran, a research associate at the Harvard Institute of Proteomics led by Dr. Josh LaBaer, and Dr. Larry Dalton, a Professor of Chemistry and Electrical engineering at the University of Washington and Nobel Prize Nominee, have both been previously featured as part of the series and are currently available to download on Lumera's website.
The podcasts are available through a variety of distribution networks and can be downloaded, among other places, at podtech.com, Apple's iTunes, Rocky Mountain Podcasting and at Lumera's own website, http://www.lumera.com/Company/Podcasts.php .
About Lumera Corporation
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit http://www.lumera.com .
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
For more information, please click here
Dr. Helene Jaillet, 425-398-6546
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|